Back to Resources
Chemistry Guide

ASO Chemistry 101: Choosing the Right Modifications

A practical guide to backbone modifications, sugar chemistries, and ASO architectures — and how to match them to your therapeutic mechanism.

10 min read•Jan 5, 2026•Beginner

Why Chemistry Matters

An unmodified oligonucleotide injected into the body would be degraded within minutes by nucleases. The entire field of ASO therapeutics exists because of chemical modifications that transform fragile nucleic acids into drug-like molecules with favorable stability, affinity, and pharmacokinetics.

Chemistry selection is not an afterthought — it fundamentally determines what your ASO can do, where it goes, and how safe it is.

Backbone Modifications

Phosphorothioate (PS)

The workhorse of ASO therapeutics. A sulfur atom replaces one non-bridging oxygen in the phosphodiester backbone, providing nuclease resistance and enabling plasma protein binding for tissue distribution.

Advantages

  • • Nuclease resistant
  • • Binds plasma proteins → tissue distribution
  • • Compatible with RNase H (in DNA gap)
  • • Used in most approved ASO drugs

Considerations

  • • Injection site reactions
  • • Complement activation at high doses
  • • Platelet effects possible
  • • Creates stereoisomers (Rp/Sp)

Phosphorodiamidate Morpholino (PMO)

A charge-neutral backbone where the ribose is replaced by a morpholine ring. Excellent safety profile but requires delivery optimization due to poor cellular uptake.

Advantages

  • • Excellent safety profile
  • • No protein binding (less off-target)
  • • Water soluble

Considerations

  • • Poor cellular uptake without conjugation
  • • Kidney accumulation
  • • Higher manufacturing cost

Sugar Modifications (2' Position)

Modifications at the 2' position of the ribose sugar increase binding affinity and nuclease resistance. The trade-off: 2'-modified nucleotides are not compatible with RNase H, which is why gapmer designs use them only in the wings.

ModificationTm BoostKey PropertiesStatus
2'-MOE+1-2°C/ntGold standard. FDA-validated in multiple drugs. Good safety.Approved
LNA+3-6°C/ntHighest affinity. Hepatotoxicity risk at high content.Approved
cEt+3-5°C/ntConstrained ethyl. Improved safety vs LNA.Clinical
2'-OMe+1°C/ntLower cost, moderate affinity. Often combined with 2'-F.Approved
2'-F+1.5°C/ntHigh nuclease resistance. Used in siRNA and some ASOs.Approved

ASO Architectures

Gapmer

For RNase H-mediated knockdown

5'- [MOE][MOE][MOE][MOE][MOE] - [DNA]×10 - [MOE][MOE][MOE][MOE][MOE] -3'
     Wings (nuclease shield)    Gap (RNase H substrate)    Wings

Modified wings protect from degradation and increase affinity. The central DNA gap recruits RNase H to cleave the target RNA. Typical designs: 5-10-5 or 3-10-3.

Mixmer

For steric blocking (splice modulation, translation blocking)

5'- [LNA]-[DNA]-[LNA]-[DNA]-[LNA]-[DNA]-[LNA]-[DNA]-[LNA] -3'
     Alternating pattern prevents RNase H recruitment

No contiguous DNA stretch means no RNase H cleavage. The ASO works purely by steric hindrance — physically blocking cellular machinery from accessing the target site.

Fully Modified (Uniform)

For steric blocking with maximum stability

5'- [MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE][MOE] -3'
     All positions carry the same 2' modification

Maximum nuclease resistance. Used for splice modulation (Nusinersen) and miRNA inhibition. Often combined with PS backbone.

Matching Chemistry to Mechanism

GoalArchitectureBackboneWings/Sugar
mRNA KnockdownGapmerPS2'-MOE o cEt
Exon SkippingMixmer o UniformPS o PMOLNA/MOE mix
Exon InclusionUniformPS2'-MOE
Translation BlockUniform o MixmerPS2'-MOE
miRNA InhibitionShort uniformPSLNA

References

1. Crooke ST et al. (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427-453. PMID: 33762737

2. Khvorova A, Watts JK. (2017) The chemical evolution of oligonucleotide therapies. Nat Biotechnol 35:238-248. PMID: 28244990

3. Hagedorn PH et al. (2018) Hepatotoxicity potential for antisense oligonucleotides. Drug Discov Today 23:101-114. PMID: 28890197

4. Shen X, Corey DR. (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides. Nucleic Acids Res 46:1584-1600. PMID: 29240946

Need Chemistry Optimization?

We help teams match the right chemistry to their mechanism, target tissue, and development stage.

Start Your Project More Resources